Review: neuro-metabolic ageing links type 2 diabetes and neurodegeneration
This review argues that type 2 diabetes and neurodegenerative disorders are interconnected manifestations of accelerated neuro-metabolic ageing, and that phytochemicals serve as illustrative multi-node modulators rather than alternative therapeutics. [1]
Automatic summary · not editorially reviewed
The key findings
The review treats type 2 diabetes and neurodegenerative disorders as interconnected manifestations of accelerated neuro-metabolic ageing rather than independent diseases. [1]
The review repositions phytochemicals not as alternative therapeutics but as biologically informative multi-node modulators, with berberine, curcumin and resveratrol given as examples. [1]
The review cites a projection that type 2 diabetes will affect 643 million people by 2030 and calls for ageing-aware models and stratified trial designs. [1]
The source at a glance
- Study type / format
- Review abstract (geroscience and network pharmacology perspective)
- Population / context
- People with or at risk of type 2 diabetes and neurodegenerative disorders, discussed at a conceptual level
- Summary based on
- Study abstract
- Original publication
- August 17, 2026
Review frames diabetes and neurodegeneration as shared ageing
The review states that ageing destabilizes metabolic and neuronal regulatory networks and raises vulnerability to type 2 diabetes and neurodegenerative disorders. It treats these conditions not as independent diseases but as interconnected manifestations of accelerated neuro-metabolic ageing. The proposed drivers are convergent impairments in insulin signaling, nutrient sensing, mitochondrial bioenergetics, redox homeostasis, proteostasis and chronic inflammation, mediated through hubs such as AMPK, mTOR, SIRT1, GSK3β and NF-κB. It notes that strategies targeting isolated molecular lesions or late-stage pathology have shown limited success in preserving cognitive and metabolic function.
Supporting source [1]
Phytochemicals as illustrative modulators of ageing hubs
Within its geroscience framework, the review repositions phytochemicals not as alternative therapeutics but as biologically informative multi-node modulators that illustrate stabilizing ageing-regulatory networks through coordinated pathway engagement. It reports that experimental and clinical evidence indicates phytochemicals engage conserved ageing hubs spanning insulin-IGF signaling, AMPK-mTOR nutrient sensing, redox regulation and mitochondrial quality control. Named examples are berberine via AMPK, curcumin via NF-κB and resveratrol via SIRT1. Translational impact remains variable, which the review attributes to constraints of bioavailability, pharmacokinetics and clinical heterogeneity.
Supporting source [1]
Projected diabetes burden and call for ageing-aware trials
The review cites a projection that type 2 diabetes will affect 643 million people by 2030. It argues that effective intervention must prioritize preservation of network resilience over correction of isolated disease endpoints, and that aligning strategies with the biology of ageing offers a more realistic pathway toward sustaining metabolic flexibility, neuronal integrity and cognitive health across the ageing trajectory. It calls for ageing-aware models and stratified trial designs. These are the review's interpretive proposals, not validated interventions or demonstrated human lifespan benefits.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no primary study design, sample, follow-up or outcome data, and the phytochemical and network claims are presented as the authors' synthesis. Translational impact is described as variable, and the proposals are not validated interventions.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Tiwari S, Siddiqui B, Fatima S, Saifi M, Khan IA, Abdin MZ. · europepmc.org · August 17, 2026